-
公开(公告)号：US20190099476A1
公开(公告)日：2019-04-04
申请号：US16161542
申请日：2018-10-16
申请人： LentigenTechnology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： A61K39/00 , C07K16/28 , C07K14/705 , C07K14/725 , A61P35/00
摘要： Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
-
公开(公告)号：US20200155661A1
公开(公告)日：2020-05-21
申请号：US16773379
申请日：2020-01-27
申请人： LentigenTechnology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： A61K39/00 , A61P35/00 , C07K14/725 , C07K14/705 , C07K16/28
摘要： Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
-
公开(公告)号：US11878052B2
公开(公告)日：2024-01-23
申请号：US16773379
申请日：2020-01-27
申请人： LentigenTechnology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： C12N15/113 , C12N15/31 , C07K14/47 , A61K35/17 , A61K39/00 , C07K16/28 , C07K14/705 , C07K14/725 , A61P35/00
CPC分类号： A61K39/001113 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K16/2803 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , C07K2317/21 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/33
摘要： Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
-
公开(公告)号：US10543263B2
公开(公告)日：2020-01-28
申请号：US16161542
申请日：2018-10-16
申请人： LentigenTechnology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： C12N15/63 , C12N15/13 , C07K14/47 , A61K39/395 , A61K39/00 , C07K16/28 , C07K14/705 , C07K14/725 , A61P35/00
摘要： Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
-
公开(公告)号：US20240108706A1
公开(公告)日：2024-04-04
申请号：US18528012
申请日：2023-12-04
申请人： LENTIGEN TECHNOLOGY, INC. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： A61K39/00 , A61P35/00 , C07K14/705 , C07K14/725 , C07K16/28
CPC分类号： A61K39/001113 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70578 , C07K16/2803 , A61K2039/505 , A61K2039/5156 , A61K2039/5158 , C07K2317/21 , C07K2317/622 , C07K2317/73 , C07K2319/00 , C07K2319/02 , C07K2319/03 , C07K2319/33
摘要： Chimeric antigen receptors (CARs) containing CD22 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the CARs are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making CAR T cells are also disclosed.
-
公开(公告)号：US20230331832A1
公开(公告)日：2023-10-19
申请号：US18317869
申请日：2023-05-15
CPC分类号： C07K16/18 , A61K47/6811 , A61K47/6843 , C07K14/78
摘要： Monoclonal antibodies and antibody fragments that specifically bind to matrilin-3, conjugates including these molecules, and nucleic acid molecules encoding the antibodies, antigen binding fragments and conjugates, are disclosed. Also disclosed are compositions including the disclosed antibodies, antigen binding fragments, conjugates, and nucleic acid molecules. Methods of treating or inhibiting a cartilage disorder in a subject, as well as methods of increasing chondrogenesis in cartilage tissue are further provided. The methods can be used, for example, for treating or inhibiting a growth plate disorder in a subject, such as a skeletal dysplasia or short stature.
-
公开(公告)号：US11708408B2
公开(公告)日：2023-07-25
申请号：US16707505
申请日：2019-12-09
申请人： LENTIGEN TECHNOLOGY, INC. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
IPC分类号： C07K16/28 , A61P35/00 , C07K14/705 , C07K14/725 , A61K35/17 , C12N5/0783 , A61K39/00 , A61K35/12
CPC分类号： C07K16/2803 , A61K35/17 , A61K39/0011 , A61K39/001112 , A61P35/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70596 , C12N5/0636 , A61K2035/124 , A61K2039/5156 , A61K2039/5158 , C07K2317/21 , C07K2317/622 , C07K2317/73 , C07K2317/76 , C07K2317/92 , C07K2319/02 , C07K2319/03 , C07K2319/035 , C07K2319/30 , C07K2319/33 , C12N2501/599 , C12N2510/00
摘要： Chimeric antigen receptors containing human CD19 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US20210324090A1
公开(公告)日：2021-10-21
申请号：US17355703
申请日：2021-06-23
发明人： Javed Khan , Sivasubramanian Baskar , Rimas J. Orentas , Dimiter S. Dimitrov , Zhongyu Zhu , Tai Chi Cheuk
IPC分类号： C07K16/28 , A61K47/68 , A61K47/69 , A61P35/00 , A61K39/395
摘要： Monoclonal antibodies selected from immunized mice, immunized rabbits and a human scFv library that specifically bind fibroblast growth factor receptor 4 (FGFR4) are described. Chimeric antigen receptors, antibody-drug conjugates, immunoconjugates, bispecific antibodies and immunoliposomes comprising the disclosed FGFR4-specific antibodies are also described. The antibody compositions can be used to diagnose or treat a FGFR4-positive cancer, such as rhabdomyosarcoma, lung cancer, liver cancer, breast cancer, pancreatic cancer or prostate cancer.
-
公开(公告)号：US11103533B2
公开(公告)日：2021-08-31
申请号：US16698186
申请日：2019-11-27
申请人： Lentigen Technology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
摘要： Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
公开(公告)号：US11045497B2
公开(公告)日：2021-06-29
申请号：US16698186
申请日：2019-11-27
申请人： Lentigen Technology, Inc. , The U.S.A., as represented by the Secretary, Department of Health and Human Services
摘要： Chimeric antigen receptors containing CD38 antigen binding domains are disclosed. Nucleic acids, recombinant expression vectors, host cells, antigen binding fragments, and pharmaceutical compositions, relating to the chimeric antigen receptors are also disclosed. Methods of treating or preventing cancer in a subject, and methods of making chimeric antigen receptor T cells are also disclosed.
-
-
-
-
-
-
-
-
-
搜索结果
34 条记录 (耗时 0.033 秒)
